Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Gyala TherapeuticsPrivate | 1 asset: 1 Ph 2 | CART84Phase 1/2 · Acute Myeloid Leukemia | 31 May 2029CART84 · Phase 1/2 |
 Gyre TherapeuticsGYRE · Nasdaq | 1 asset: 1 Ph 1 | F230Phase 1 · Hypertension | None on record |
 HELP TherapeuticsPrivate | 1 asset: 1 Ph 3 | HiCM-188 (allogeneic iPSC-cardiomyocytes)Phase 3 · Heart FailurePartial signal | 10 Nov 2026HiCM-188 (allogeneic iPSC-cardiomyocytes) · Phase 1/2 |
 HLS Therapeutics Inc.HLS · TSX | 1 asset: 1 approved | Approved assets only | None on record |
 HMNC Brain HealthPrivate | 1 asset: 1 Ph 2 | NelivaptanPhase 2 · Major Depressive DisorderPartial signal | None on record |
 Haihe BiopharmaPrivate | 1 asset: 1 Ph 3 | GlumetinibPhase 3 · Non-Small Cell Lung Cancer | None on record |
 Halia TherapeuticsPrivate | 1 asset: 1 Ph 2 | HT-4253Phase 2 · Alzheimer's Disease | Feb 2028HT-4253 · Phase 2 |
 Handa Neuroscience, LLCPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Hangzhou Dinovate BiotechPrivate | 1 asset: 1 Ph 2 | DNV001Phase 2 · Atherosclerotic Cardiovascular Disease | 30 Jun 2027DNV001 · Phase 2 |
| 1 asset: 1 Ph 1 | HPB-092Phase 1 · Acute Myeloid Leukemia | Jun 2027HPB-092 · Phase 1 | |
| 1 asset: 1 Ph 1 | WBC100Phase 1 · Acute Myeloid Leukemia | None on record | |
 Hansa BiopharmaHNSA · Nasdaq Stockholm | 1 asset: 1 Ph 3 | ImlifidasePhase 3 · Chronic Kidney DiseaseWeak signal | 28 Feb 2027Imlifidase · Phase 2 |
 Harbour BioMedPrivate | 1 asset: 1 Ph 2 | WIN378Phase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | Jul 2027WIN378 · Phase 2 |
 HeartWorksPrivate | 1 asset: 1 Ph 1 | iPSC-CLPhase 1 · Heart Failure | Sep 2027iPSC-CL · Phase 1 |
 Heartseed219A · TSE | 1 asset: 1 Ph 2 | HS-001Phase 1/2 · Heart Failure | None on record |
| 1 asset: 1 Ph 1 | TGI-5Phase 1 · Non-Small Cell Lung Cancer | 31 Oct 2027TGI-5 · Phase 1 | |
 Heidelberg Pharma AGHPHA · Xetra | 1 asset: 1 Ph 2 | Pamlectabart tismanitinPhase 1/2 · Multiple Myeloma | Mar 2028Pamlectabart tismanitin · Phase 1/2 |
 Helix BioPharma Corp.HBP · TSX | 1 asset: 1 Ph 2 | L-DOS47Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
 Helixmith Co., Ltd.084990 · KOSDAQ | 1 asset: 1 Ph 3 | Beperminogene perplasmid (HGF plasmid)Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
 Hemostemix Inc.HEM · TSXV | 1 asset: 1 Ph 2 | ACP-01Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 HighTide BiopharmaPrivate | 1 asset: 1 Ph 3 | HTD1801Phase 3 · Type 2 DiabetesReliable signal | None on record |
 Hikma Pharmaceuticals PLCHIK · LSE | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 2 | HBI-002Phase 2 · Parkinson's Disease | 31 Dec 2026HBI-002 · Phase 2 | |
| 1 asset: 1 approved | Approved assets only | None on record | |
| 1 asset: 1 Ph 2 | WD-1603Phase 2 · Parkinson's DiseasePartial signal | None on record | |
 HumacyteHUMA · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 Humanetics CorporationPrivate | 1 asset: 1 Ph 2 | BIO 300Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record |
 HuniLife Biotechnology, Inc.Private | 1 asset: 1 Ph 2 | HuL001Phase 1/2 · Multiple Myeloma | 30 Nov 2027HuL001 · Phase 1/2 |
 Huons084110 · KOSDAQ | 1 asset: 1 Ph 1 | HUC2-676Phase 1 · Obesity | None on record |
| 1 asset: 1 approved | Approved assets only | None on record | |
 IASO BiotherapeuticsPrivate | 1 asset: 1 Ph 1 | CAR-GPRC5D (RD118, IASO Biotherapeutics)Phase 1 · Multiple Myeloma | None on record |
| 1 asset: 1 Ph 2 | IDP-121Phase 1/2 · Multiple Myeloma | None on record | |
 INmune BioINMB · Nasdaq | 1 asset: 1 Ph 2 | XPro1595Phase 2 · Alzheimer's DiseasePartial signal | None on record |
 ITM Oncologics GmbHITM · Nasdaq | 1 asset: 1 Ph 2 | 177Lu-DPI-4452Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Iambic Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | IAM1363Phase 1 · Non-Small Cell Lung Cancer | Dec 2027IAM1363 · Phase 1 |
 Idorsia PharmaceuticalsIDIA · SIX | 1 asset: 1 approved | Approved assets only | None on record |
 IlDong Pharmaceutical Co., Ltd.249420 · KOSPI | 1 asset: 1 Ph 2 | Besifovir dipivoxil (Besivo)Phase 2 · Chronic Hepatitis B | None on record |
| 1 asset: 1 Ph 1 | IBR733Phase 1 · Acute Myeloid Leukemia | 1 Jul 2027IBR733 · Phase 1 | |
 Imbria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NinerafaxstatPhase 2 · Heart FailureWeak signal | Dec 2026Ninerafaxstat · Phase 2 |
 ImmVira PharmaPrivate | 1 asset: 1 Ph 2 | T3011Phase 1/2 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2028T3011 · Phase 2 |
 Immedica Pharma ABPrivate | 1 asset: 1 approved | Approved assets only | Dec 2029Ganaxolone · Phase 3 |
 Immune-Onc TherapeuticsPrivate | 1 asset: 1 Ph 1 | IO-202Phase 1 · Acute Myeloid LeukemiaWeak signal | None on record |
 Immuneering CorporationIMRX · Nasdaq | 1 asset: 1 Ph 2 | IMM-1-104Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Immunitas TherapeuticsPrivate | 1 asset: 1 Ph 2 | IMT-009Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Immuno Cure BioTechPrivate | 1 asset: 1 Ph 1 | AV000103A (ICVAX)Phase 1 · HIVPartial signal | None on record |
 Immunobrain CheckpointPrivate | 1 asset: 1 Ph 1 | IBC-Ab002Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Immunophotonics, Inc.Private | 1 asset: 1 Ph 3 | IP-001Phase 2/3 · Non-Small Cell Lung Cancer | Dec 2033IP-001 · Phase 2/3 |
 ImmunworkPrivate | 1 asset: 1 Ph 2 | TE-8105Phase 1/2 · ObesityWeak signal | None on record |
 Incendia TherapeuticsPrivate | 1 asset: 1 Ph 1 | PRTH-101Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Indapta Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | IDP-023Phase 1/2 · Multiple Myeloma | None on record |
| 1 asset: 1 Ph 2 | Decoy20Phase 1/2 · Non-Small Cell Lung Cancer | 30 Jun 2027Decoy20 · Phase 1/2 | |
 Indication BioSciencePrivate | 1 asset: 1 Ph 1 | Atorvo+Phase 1 · Atherosclerotic Cardiovascular DiseaseWeak signal | None on record |
 InduPro, Inc.Private | 1 asset: 1 Ph 2 | IDP-001Phase 1/2 · Non-Small Cell Lung Cancer | Jun 2028IDP-001 · Phase 1/2 |
 Inhatarget TherapeuticsPrivate | 1 asset: 1 Ph 2 | CIS-DPIPhase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Inmagene BiopharmaceuticalsIMA · Nasdaq | 1 asset: 1 Ph 2 | IMG-007Phase 2 · Atopic DermatitisWeak signal | Dec 2027IMG-007 · Phase 2 |
 InnoMedica Schweiz AGPrivate | 1 asset: 1 Ph 2 | TalineurenPhase 2 · Parkinson's DiseasePartial signal | None on record |
 Innopeutics CorporationPrivate | 1 asset: 1 Ph 1 | IPS101APhase 1 · Parkinson's Disease | 31 Oct 2027IPS101A · Phase 1 |
 Innovo TherapeuticsPrivate | 1 asset: 1 Ph 1 | INV-101Phase 1 · Ulcerative ColitisPartial signal | None on record |
 Inovio Pharmaceuticals, Inc.INO · Nasdaq | 1 asset: 1 Ph 2 | INO-3107Phase 1/2 · Recurrent Respiratory Papillomatosis | None on record |
 Inozyme PharmaPrivate | 1 asset: 1 Ph 3 | INZ-701Phase 3 · Chronic Kidney DiseaseWeak signal | 14 Oct 2026INZ-701 · Phase 1 |
 Insilico Medicine3696 · HKEX | 1 asset: 1 Ph 2 | garutadustatPhase 2 · Ulcerative Colitis | 15 Aug 2027garutadustat · Phase 2 |
 Integro TheranosticsPrivate | 1 asset: 1 Ph 2 | LS301-ITPhase 2 · Non-Small Cell Lung Cancer | None on record |
| 1 asset: 1 Ph 3 | DapivirinePhase 3 · HIVPartial signal | None on record | |
| 1 asset: 1 Ph 1 | ISC-hpNSCPhase 1 · Parkinson's DiseaseWeak signal | None on record | |
 IntoCell, Inc287840 · KOSDAQ | 1 asset: 1 Ph 1 | ITC-6146ROPhase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027ITC-6146RO · Phase 1 |
 IntralytixPrivate | 1 asset: 1 Ph 2 | EcoActivePhase 1/2 · Crohn's Disease | None on record |
 InventisBio688382 · SSE STAR Market | 1 asset: 1 Ph 3 | D-2570Phase 3 · Ulcerative ColitisPartial signal | 31 Oct 2026D-2570 · Phase 1 |
 InventivaIVA · Nasdaq | 1 asset: 1 Ph 3 | LanifibranorPhase 3 · Type 2 DiabetesPartial signal | 30 Sep 2027Lanifibranor · Phase 3 |
Invenux, LLCPrivate | 1 asset: 1 Ph 1 | SCD-101Phase 1 · Sickle Cell Disease | None on record |
 Inversago PharmaPrivate | 1 asset: 1 Ph 2 | INV-202Phase 2 · ObesityPartial signal | None on record |
 InxMedPrivate | 1 asset: 1 Ph 3 | IN10018Phase 3 · Non-Small Cell Lung Cancer | 24 Dec 2026IN10018 · Phase 2 |
 Io TherapeuticsPrivate | 1 asset: 1 Ph 2 | IRX4204Phase 2 · PsoriasisWeak signal | None on record |
 Iperboreal PharmaPrivate | 1 asset: 1 Ph 2 | PolyCorePhase 1/2 · Heart Failure | Dec 2026PolyCore · Phase 1/2 |
 IpsenIPN · Euronext Paris | 1 asset: 1 Ph 2 | Mesdopetam (IRL790)Phase 2 · Parkinson's DiseasePartial signal | None on record |
 J Ints BioPrivate | 1 asset: 1 Ph 2 | JIN-A02Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
JMackem Co., Ltd.Private | 1 asset: 1 Ph 1 | AJH-2947Phase 1 · Diabetic Peripheral Neuropathic PainPartial signal | None on record |
 Jaguar HealthJAGX · Nasdaq | 1 asset: 1 approved | Approved assets only | Dec 2026Crofelemer · Phase 2/3 |
 Japan TobaccoPrivate | 1 asset: 1 Ph 3 | DalcetrapibPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | Aug 2027Dalcetrapib · Phase 3 |
 Jasper Therapeutics, Inc.JSPR · Nasdaq | 1 asset: 1 Ph 2 | BriquilimabPhase 2 · AsthmaPartial signal | None on record |
 Jecho BiopharmaceuticalsPrivate | 1 asset: 1 Ph 2 | JL18008Phase 1/2 · HIVPartial signal | 12 Feb 2027JL18008 · Phase 1/2 |
 Jeil PharmaceuticalPrivate | 1 asset: 1 Ph 3 | JT-001Phase 3 · Type 2 DiabetesReliable signal | None on record |
| 1 asset: 1 Ph 3 | FHND9041Phase 3 · Non-Small Cell Lung Cancer | None on record | |
| 1 asset: 1 Ph 3 | GS101Phase 3 · Atopic Dermatitis | Apr 2027GS101 · Phase 3 | |
| 1 asset: 1 Ph 3 | TH-SC01Phase 3 · Crohn's DiseaseWeak signal | 28 Dec 2026TH-SC01 · Phase 3 | |
| 1 asset: 1 Ph 3 | VicagrelPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | 30 Dec 2026Vicagrel · Phase 3 | |
 Jiangsu Vcare PharmatechPrivate | 1 asset: 1 Ph 3 | VC005Phase 3 · Atopic Dermatitis | None on record |
 Jina PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | nanosomal tacrolimusPhase 2 · Ulcerative Colitis | None on record |
 Juno Therapeutics, Inc.Private | 1 asset: 1 Ph 3 | Arlocabtagene autoleucelPhase 3 · Multiple MyelomaWeak signal | 30 Dec 2027Arlocabtagene autoleucel · Phase 3 |
 K36 Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | KTX-1001Phase 1 · Multiple Myeloma | 31 Dec 2027KTX-1001 · Phase 1 |
 Kahr MedicalPrivate | 1 asset: 1 Ph 2 | DSP107Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 Kaken Pharmaceutical4521 · TSE | 1 asset: 1 Ph 3 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 |
 KaliVir ImmunotherapeuticsPrivate | 1 asset: 1 Ph 1 | VET3-TGIPhase 1 · Non-Small Cell Lung Cancer | 30 Sep 2027VET3-TGI · Phase 1 |
 KallyopePrivate | 1 asset: 1 Ph 3 | ElismetrepPhase 3 · Migraine | Feb 2027Elismetrep · Phase 3 |
 Kamau Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | Nula-celPhase 1/2 · Sickle Cell Disease | 31 Dec 2026Nula-cel · Phase 1/2 |
 Kangstem Biotech217730 · KOSDAQ | 1 asset: 1 Ph 3 | Furestem-CDPhase 3 · Crohn's DiseaseWeak signal | None on record |
 Kariya PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | KP405Phase 1 · Parkinson's DiseasePartial signal | None on record |
 Kelonia Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | KLN-1010Phase 1 · Multiple Myeloma | Mar 2027KLN-1010 · Phase 1 |
 Kenai TherapeuticsPrivate | 1 asset: 1 Ph 2 | RNDP-001Phase 1/2 · Parkinson's Disease | Sep 2027RNDP-001 · Phase 1/2 |
 Kestrel TherapeuticsPrivate | 1 asset: 1 Ph 1 | KST-6051Phase 1 · Non-Small Cell Lung Cancer | Jun 2027KST-6051 · Phase 1 |
 Keystone Nano, IncPrivate | 1 asset: 1 Ph 1 | Ceramide NanoLiposome (Ceraxa)Phase 1 · Acute Myeloid Leukemia | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).